Cargando…

Mutation analysis of circulating plasma DNA to determine response to EGFR tyrosine kinase inhibitor therapy of lung adenocarcinoma patients

Long-lasting success in lung cancer therapy using tyrosine kinase inhibitors (TKIs) is rare since the tumors develop resistance due to the occurrence of molecularly altered subclones. The aim of this study was to monitor tumors over time based on the quantity of mutant plasma DNA and to identify ear...

Descripción completa

Detalles Bibliográficos
Autores principales:	Riediger, Anja Lisa, Dietz, Steffen, Schirmer, Uwe, Meister, Michael, Heinzmann-Groth, Ingrid, Schneider, Marc, Muley, Thomas, Thomas, Michael, Sültmann, Holger
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5027592/ https://www.ncbi.nlm.nih.gov/pubmed/27640882 http://dx.doi.org/10.1038/srep33505

Ejemplares similares

Low Input Whole-Exome Sequencing to Determine the Representation of the Tumor Exome in Circulating DNA of Non-Small Cell Lung Cancer Patients
por: Dietz, Steffen, et al.
Publicado: (2016)

Patient-specific molecular alterations are associated with metastatic clear cell renal cell cancer progressing under tyrosine kinase inhibitor therapy
por: Dietz, Steffen, et al.
Publicado: (2017)

Longitudinal monitoring of cell-free DNA methylation in ALK-positive non-small cell lung cancer patients
por: Janke, Florian, et al.
Publicado: (2022)

Molecular signatures in IASLC/ATS/ERS classified growth patterns of lung adenocarcinoma
por: Zabeck, Heike, et al.
Publicado: (2018)

Pathways regulating the expression of the immunomodulatory protein glycodelin in non-small cell lung cancer
por: Weber, Rebecca, et al.
Publicado: (2018)

Early identification of disease progression in ALK-rearranged lung cancer using circulating tumor DNA analysis
por: Angeles, Arlou Kristina, et al.
Publicado: (2021)

Integrated circulating tumour DNA and cytokine analysis for therapy monitoring of ALK-rearranged lung adenocarcinoma
por: Angeles, Arlou Kristina, et al.
Publicado: (2023)

Assessment of EGFR gene mutations in circulating free DNA in monitoring of response to EGFR tyrosine kinase inhibitors in patients with lung adenocarcinoma
por: Nicoś, Marcin, et al.
Publicado: (2019)

Novel Liquid Biomarker Panels for A Very Early Response Capturing of NSCLC Therapies in Advanced Stages
por: Janke, Florian, et al.
Publicado: (2020)

Serial liquid biopsies for detection of treatment failure and profiling of resistance mechanisms in KLC1–ALK-rearranged lung cancer
por: Dietz, Steffen, et al.
Publicado: (2019)

Multiple layers of intratumor heterogeneity: clues to clonal evolution of non-small cell lung cancer
por: Dietz, Steffen, et al.
Publicado: (2019)

Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma
por: Budczies, Jan, et al.
Publicado: (2021)

Defining molecular risk in ALK(+) NSCLC
por: Christopoulos, Petros, et al.
Publicado: (2019)

Early responses of EGFR circulating tumor DNA to EGFR tyrosine kinase inhibitors in lung cancer treatment
por: Imamura, Fumio, et al.
Publicado: (2016)

Uncommon EGFR mutations in lung adenocarcinoma: features and response to tyrosine kinase inhibitors
por: Brindel, Aurélien, et al.
Publicado: (2020)

Liquid Biopsies beyond Mutation Calling: Genomic and Epigenomic Features of Cell-Free DNA in Cancer
por: Angeles, Arlou Kristina, et al.
Publicado: (2021)

EGFR Mutation Status in Lung Adenocarcinoma-Associated Malignant Pleural Effusion and Efficacy of EGFR Tyrosine Kinase Inhibitors
por: Yang, Jiyoul, et al.
Publicado: (2018)

Improved survival in patients with unresectable stage III EGFR ‐mutant adenocarcinoma with upfront EGFR‐tyrosine kinase inhibitors
por: Wang, Sheng‐Yuan, et al.
Publicado: (2021)

Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNA
por: Dietz, Steffen, et al.
Publicado: (2020)

Transmembrane serine protease 2 is a prognostic factor for lung adenocarcinoma
por: Schneider, Marc A., et al.
Publicado: (2022)

Biomarkers for the Detection and Risk Stratification of Aggressive Prostate Cancer
por: Eickelschulte, Samaneh, et al.
Publicado: (2022)

Lung adenocarcinoma patients of young age have lower EGFR mutation rate and poorer efficacy of EGFR tyrosine kinase inhibitors
por: Wu, Shang-Gin, et al.
Publicado: (2017)

The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients
por: Wu, Shang-Gin, et al.
Publicado: (2016)

Intratumoral Heterogeneity and Immune Modulation in Lung Adenocarcinoma in Female Smokers and Never Smokers
por: Trefzer, Timo B., et al.
Publicado: (2022)

Cross-talk between AMPK and EGFR dependent Signaling in Non-Small Cell Lung Cancer
por: Praveen, Paurush, et al.
Publicado: (2016)

Iron accumulation in tumor-associated macrophages marks an improved overall survival in patients with lung adenocarcinoma
por: Thielmann, Carl Maximilian, et al.
Publicado: (2019)

A case of EGFR mutant lung adenocarcinoma that acquired resistance to EGFR-tyrosine kinase inhibitors with MET amplification and epithelial-to-mesenchymal transition
por: Miyoshi, Seigo, et al.
Publicado: (2015)

Association of EGFR Tyrosine Kinase Inhibitor Treatment With Progression-Free Survival Among Taiwanese Patients With Advanced Lung Adenocarcinoma and EGFR Mutation
por: Chen, Po-Yen, et al.
Publicado: (2021)

Comprehensive serial biobanking in advanced NSCLC: feasibility, challenges and perspectives
por: Wessels, Sabine, et al.
Publicado: (2020)

The prognostic value of CT radiomic features for patients with pulmonary adenocarcinoma treated with EGFR tyrosine kinase inhibitors
por: Kim, Hyungjin, et al.
Publicado: (2017)

Different mutational characteristics of the subsets of EGFR-tyrosine kinase inhibitor sensitizing mutation-positive lung adenocarcinoma
por: Kim, Eun Young, et al.
Publicado: (2018)

MUSASHI‐2 confers resistance to third‐generation EGFR‐tyrosine kinase inhibitor osimertinib in lung adenocarcinoma
por: Yiming, Reheman, et al.
Publicado: (2021)

Mechanisms of resistance to EGFR tyrosine kinase inhibitors
por: Huang, Lihua, et al.
Publicado: (2015)

Kinase-Inactivated EGFR Is Required for the Survival of Wild-Type EGFR-Expressing Cancer Cells Treated with Tyrosine Kinase Inhibitors
por: Thomas, Rintu, et al.
Publicado: (2019)

Fibroblast Growth Factor—14 Acts as Tumor Suppressor in Lung Adenocarcinomas
por: Turkowski, Kati, et al.
Publicado: (2020)

Survival-associated factors of first-line EGFR-tyrosine kinase inhibitor responders and non-responders in lung adenocarcinoma patients with common EGFR mutations
por: Hung, Ming-Szu, et al.
Publicado: (2018)

Comparative effectiveness of concurrent chemoradiotherapy versus EGFR‐tyrosine kinase inhibitors for the treatment of clinical stage IIIb lung adenocarcinoma patients with mutant EGFR
por: Hsia, Te‐Chun, et al.
Publicado: (2018)

A real-world study comparing perioperative chemotherapy and EGFR-tyrosine kinase inhibitors for treatment of resected stage III EGFR-mutant adenocarcinoma
por: Chen, Chieh-Lung, et al.
Publicado: (2023)

Earlier extracranial progression and shorter survival in ALK-rearranged lung cancer with positive liquid rebiopsies
por: Christopoulos, Petros, et al.
Publicado: (2021)

Imaging of EGFR and EGFR Tyrosine Kinase Overexpression in Tumors by Nuclear Medicine Modalities
por: Mishani, Eyal, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_i9qjl90pdlat83p0a5re0hqd35